Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CABA Cabaletta Bio	$1.73 -7.5%	$1.60	$0.99 ▼ $9.25	$87.79M	2.81	1.64 million shs	3.33 million shs
CRGX CARGO Therapeutics	$4.35 -0.5%	$4.34	$3.00 ▼ $25.45	$200.58M	0.31	571,948 shs	297,373 shs
FDMT 4D Molecular Therapeutics	$4.09 -1.4%	$3.57	$2.24 ▼ $28.93	$189.47M	2.84	828,000 shs	341,200 shs
IMTX Immatics	$5.85 -4.7%	$5.08	$3.30 ▼ $13.09	$711.07M	0.83	660,643 shs	589,394 shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CABA Cabaletta Bio	0.00%	-3.89%	-7.98%	-0.57%	-79.28%
CRGX CARGO Therapeutics	0.00%	-2.90%	+6.10%	+4.07%	-71.81%
FDMT 4D Molecular Therapeutics	0.00%	-9.11%	+6.23%	+4.34%	-82.05%
IMTX Immatics	0.00%	-4.72%	+8.33%	+17.00%	-53.50%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CABA Cabaletta Bio	2.7716 of 5 stars	4.5	1.0	2.6	0.8	0.6
CRGX CARGO Therapeutics	1.5617 of 5 stars	2.9	0.0	0.6	1.7	1.3
FDMT 4D Molecular Therapeutics	2.3914 of 5 stars	3.3	3.0	2.0	1.7	0.6
IMTX Immatics	2.2834 of 5 stars	3.6	3.0	2.0	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CABA Cabaletta Bio	3.00	Buy	$18.88	991.04% Upside
CRGX CARGO Therapeutics	1.86	Reduce	$15.00	244.83% Upside
FDMT 4D Molecular Therapeutics	2.60	Moderate Buy	$29.56	622.63% Upside
IMTX Immatics	3.20	Buy	$14.67	150.71% Upside

Current Analyst Ratings Breakdown

Latest IMTX, CABA, CRGX, and FDMT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/11/2025	CABA Cabaletta Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00
6/11/2025	FDMT 4D Molecular Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (D-)
5/28/2025	IMTX Immatics	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$10.00
5/24/2025	FDMT 4D Molecular Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)
5/16/2025	CABA Cabaletta Bio	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$17.00 ➝ $13.00
5/15/2025	CABA Cabaletta Bio	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$23.00 ➝ $25.00
5/10/2025	FDMT 4D Molecular Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (E+) ➝ Sell (E+)
5/9/2025	FDMT 4D Molecular Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$28.00 ➝ $25.00
5/9/2025	FDMT 4D Molecular Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$51.00 ➝ $44.00
5/9/2025	FDMT 4D Molecular Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$45.00 ➝ $38.00
4/24/2025	FDMT 4D Molecular Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sell (D-) ➝ Sell (E+)

(Data available from 6/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CABA Cabaletta Bio	N/A	N/A	N/A	N/A	$3.12 per share	N/A
CRGX CARGO Therapeutics	N/A	N/A	N/A	N/A	$7.83 per share	N/A
FDMT 4D Molecular Therapeutics	$40K	4,737.24	N/A	N/A	$11.05 per share	0.37
IMTX Immatics	$168.65M	4.22	$0.24 per share	23.94	$5.12 per share	1.14

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CABA Cabaletta Bio	-$115.86M	-$2.54	N/A	N/A	N/A	N/A	-78.29%	-65.68%	8/6/2025 (Estimated)
CRGX CARGO Therapeutics	-$167.50M	-$4.62	N/A	N/A	N/A	N/A	-45.93%	-39.58%	8/11/2025 (Estimated)
FDMT 4D Molecular Therapeutics	-$160.87M	-$3.18	N/A	N/A	N/A	-767,126.06%	-33.26%	-30.68%	8/14/2025 (Estimated)
IMTX Immatics	$16.47M	-$0.17	N/A	N/A	N/A	-14.73%	-4.52%	-3.34%	8/12/2025 (Estimated)

Latest IMTX, CABA, CRGX, and FDMT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/21/2025	Q1 2025	CABA Cabaletta Bio	-$0.67	-$0.71	-$0.04	-$0.71	N/A	N/A
5/13/2025	Q1 2025	IMTX Immatics	-$0.39	-$0.35	+$0.04	-$0.35	$14.92 million	$20.12 million
5/8/2025	Q1 2025	FDMT 4D Molecular Therapeutics	-$0.84	-$0.86	-$0.02	-$0.86	$0.53 million	N/A
3/31/2025	Q4 2024	CABA Cabaletta Bio	-$0.65	-$0.65	N/A	-$0.65	N/A	N/A
3/27/2025	Q4 2024	IMTX Immatics	-$0.03	$0.48	+$0.51	$0.48	$16.16 million	$15.67 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CABA Cabaletta Bio	N/A	N/A	N/A	N/A	N/A
CRGX CARGO Therapeutics	N/A	N/A	N/A	N/A	N/A
FDMT 4D Molecular Therapeutics	N/A	N/A	N/A	N/A	N/A
IMTX Immatics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CABA Cabaletta Bio	N/A	3.96	3.96
CRGX CARGO Therapeutics	N/A	6.30	6.30
FDMT 4D Molecular Therapeutics	N/A	12.36	12.36
IMTX Immatics	N/A	10.28	10.28

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CABA Cabaletta Bio	N/A
CRGX CARGO Therapeutics	93.16%
FDMT 4D Molecular Therapeutics	99.27%
IMTX Immatics	64.41%

Insider Ownership

Company	Insider Ownership
CABA Cabaletta Bio	11.25%
CRGX CARGO Therapeutics	2.92%
FDMT 4D Molecular Therapeutics	9.60%
IMTX Immatics	3.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CABA Cabaletta Bio	50	50.74 million	45.03 million	Optionable
CRGX CARGO Therapeutics	116	46.11 million	44.76 million	N/A
FDMT 4D Molecular Therapeutics	120	46.33 million	41.88 million	Optionable
IMTX Immatics	260	121.55 million	117.54 million	Optionable

IMTX, CABA, CRGX, and FDMT Headlines

Recent News About These Companies

Immatics (NASDAQ:IMTX) Shares Down 3.8% - Here's Why

June 18 at 5:15 PM | marketbeat.com

Immatics N.V. Shareholders Approve Key Resolutions at June 2025 AGM

June 18 at 2:22 PM | tipranks.com

Immatics (NASDAQ:IMTX) Shares Up 4.4% - Here's What Happened

June 12, 2025 | marketbeat.com

Cantor Fitzgerald Weighs in on Immatics FY2026 Earnings

June 12, 2025 | americanbankingnews.com

Immatics (NASDAQ:IMTX) Sees Unusually-High Trading Volume - Here's What Happened

June 11, 2025 | marketbeat.com

Cantor Fitzgerald Forecasts Immatics FY2026 Earnings

June 10, 2025 | marketbeat.com

Immatics (NASDAQ:IMTX) Shares Down 4.9% - Should You Sell?

June 9, 2025 | marketbeat.com

Millennium Management LLC Has $1.11 Million Holdings in Immatics (NASDAQ:IMTX)

June 5, 2025 | marketbeat.com

Immatics: Taking Off On A PRAME Rocketship

June 4, 2025 | seekingalpha.com

Does Immatics (IMTX) Have the Potential to Rally 174.54% as Wall Street Analysts Expect?

June 3, 2025 | zacks.com

Immatics rises on data from early stage cell therapy trial

June 2, 2025 | msn.com

Immatics Presents Promising IMA203 Data at ASCO 2025

June 2, 2025 | tipranks.com

Immatics (IMTX) Shares Promising Data from IMA203 Melanoma Trials | IMTX Stock News

June 1, 2025 | gurufocus.com

Immatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to ...

May 31, 2025 | gurufocus.com

Immatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to ...

May 31, 2025 | gurufocus.com

Immatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to ...

May 31, 2025 | gurufocus.com

Immatics N.V. Reports Promising Long-Term Efficacy and Safety Data from Phase 1b Trial of IMA203 PRAME Cell Therapy in Metastatic Melanoma

May 31, 2025 | quiverquant.com

Immatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to Show Strong Anti-tumor Activity and Durability in Patients with Metastatic Melanoma

May 31, 2025 | globenewswire.com

Wellington Management Group LLP Grows Position in Immatics (NASDAQ:IMTX)

May 30, 2025 | marketbeat.com

Immatics (NASDAQ:IMTX) Trading Up 4.1% - Time to Buy?

May 29, 2025 | marketbeat.com

Immatics (NASDAQ:IMTX) Given Average Recommendation of "Buy" by Brokerages

May 29, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMTX, CABA, CRGX, and FDMT Company Descriptions

Cabaletta Bio NASDAQ:CABA

$1.73 -0.14 (-7.49%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$1.76 +0.02 (+1.45%)

As of 06/18/2025 07:51 PM Eastern

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, which is in Phase I/II clinical trial for the treatment of mucosal pemphigus vulgaris; and MuSK-CAART, an investigational cell therapy that is in Phase I/II clinical trial for treating patients with anti- muscle-specific kinase antibody positive myasthenia gravis. It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

CARGO Therapeutics NASDAQ:CRGX

$4.35 -0.02 (-0.46%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$4.35 0.00 (0.00%)

As of 06/18/2025 04:01 PM Eastern

CARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies. It also develops CRG-023, a tri-specific CAR T product candidate that targets tumor cells with three B-cell antigen targets. The company was formerly known as Syncopation Life Sciences, Inc. and changed its name to CARGO Therapeutics, Inc. in September 2022. CARGO Therapeutics, Inc. was incorporated in 2019 and is headquartered in San Mateo, California.

4D Molecular Therapeutics NASDAQ:FDMT

$4.09 -0.06 (-1.45%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$4.09 0.00 (-0.10%)

As of 06/18/2025 06:27 PM Eastern

4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.

Immatics NASDAQ:IMTX

$5.85 -0.29 (-4.72%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$6.02 +0.18 (+2.99%)

As of 06/18/2025 06:26 PM Eastern

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time